Comparison of insulin resistance in the various stages of chronic kidney disease and inflammation

References

• Nazarians-Armavil A, Chalmers JA, Lee CB, Ye W, Belsham DD. Cellular insulin resistance disrupts hypothalamic mHypoA-POMC/GFP neuronal signaling pathways. J Endocrinol. 2013;220(1):13–24
   PubMedGoogle Scholar
• Martin-Gronert MS, Ozanne SE. Metabolic programming of insulin action and secretion. Diabetes Obes Metab. 2012;14(Suppl. 3):29–39
   PubMedGoogle Scholar
• Benito M. Tissue-specificity of insulin action and resistance. Arch Physiol Biochem. 2011;117(3):96–104
   PubMedGoogle Scholar
• Hurskainen AR, Virtanen JK, Tuomainen TP, Nurmi T, Voutilainen S. Association of serum 25-hydroxyvitamin D with type 2 diabetes and markers of insulin resistance in a general older population in Finland. Diabetes Metab Res Rev. 2012;28(5):418–423
   PubMedGoogle Scholar
• Hung AM, Ikizler TA. Factors determining insulin resistance in chronic hemodialysis patients. Contrib Nephrol. 2011;171:127–134
   PubMedGoogle Scholar
• Siew ED, Ikizler TA. Insulin resistance and protein energy metabolism in patients with advanced chronic kidney disease. Semin Dial. 2010;23(4):378–382
   PubMedGoogle Scholar
• Peng YS, Chiu YL, Chen HY, et al. Decreased highdensity lipoprotein cholesterol is associated with inflammation and insulin resistance in non-diabetic hemodialysis patients. Nephrology. 2010;15(7):692–699
   PubMedGoogle Scholar
• Caccamo G, Bonura F, Vitale G, Evola G, Grisanti MR, Novo S. Insulin resistnce and acute coronary syndrome. Atherosclerosis. 2010;211(2):672–675
   PubMed Web of Science ®Google Scholar
• Allon M. Evidence-based cardiology in hemodialysis patients. Am Soc Nephrol. 2013;24(12):1934–1943
   PubMed Web of Science ®Google Scholar
• Paneni F, Costantino S, Cosentino F. Insulin resistance, diabetes, and cardiovascular risk. Curr Atheroscler Rep. 2014;16(7):414–419
   PubMedGoogle Scholar
• Caravaca F, Cerezo I, Macías R, et al. Insulin resistance in chronic kidney disease: Its clinical characteristics and prognosis significance. Nefrologia. 2010;30(6):661–668
   PubMed Web of Science ®Google Scholar
• Hage Hassan R, Bourron O, Hajduch E. Defect of insulin signal in peripheral tissues: Important role of ceramide. World J Diabetes. 2014;5(3):244–257
   PubMedGoogle Scholar
• Kobayashi S, Maejima S, Ikeda T, Nagase M. Impact of dialysis therapy on insulin resistance in end- stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2000;15(1):65–70
   Google Scholar
• Satirapoj B, Supasyndh O, Phantana Angkul P, et al. Insulin resistance in dialysis versus nondialysis end stage renal disease patients without diabetes. J Med Assoc Thai. 2011;94(Suppl. 4):S87–S93
   PubMedGoogle Scholar
• Plourde M, Vohl MC, Bellis C, et al. A variant in the LRRFIP1 gene is associated with adiposity and inflammation. Obesity (Silver Spring). 2013;21(1):185–192
   PubMedGoogle Scholar
• Afsar B, Turkmen K, Covic A, Kanbay M. An update on coronary artery disease and chronic kidney disease. Int J Nephrol. 2014;2014:767424
   PubMedGoogle Scholar
• Dashti N, Einollahi N, Nabatchian F, Moradi Sarabi M, Zarebavani M. Significance of albumin and C-reactive protein variations in 300 end stage renal disease patients in Tehran University of Medical Sciences Hospitals during year 2010. Acta Med Iran. 2012;50(3):197–202
   PubMedGoogle Scholar
• Marinelli A, Orlandi L, Stivali G. C-reactive protein levels are associated with arterial media calcification in nondiabetic patients with end stage renal disease on long term hemodialysis. Clin Nephrol. 2011;76(6):425–434
   PubMedGoogle Scholar
• Borazan A, Binici DN. Relationship between insulin resistance and inflamation markers in hemodialysis patients. Ren Fail. 2010;32(2):198–202
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Carrero JJ, Stenvinkel P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens. 2011;20(6):662–668
   PubMedGoogle Scholar
• Soonthornpun S, Setasuban W, Thamprasit A. Correlation between change in serum homocysteine levels during hyperinsulinemia and insulin sensivity. J Med Assoc Thoi. 2007;90(8):1506–1511
   PubMedGoogle Scholar
• Cho MJ, Kim MS, Kim CJ, et al. Fasting serum C-peptide is useful for initial classification of diabetes mellitus in children and adolescents. Ann Pediatr Endocrinol Metab. 2014;19(2):80–85. doi:10.6065/apem.2014.19.2.80. [Epub 2014 Jun 30]
   PubMedGoogle Scholar
• Marx N, Walcher D. C-peptide and atherogenesis: C-peptide as a mediator of lesion development in patients with type 2 diabetes mellitus? Exp Diabetes Res. 2008;2008:385108
   PubMedGoogle Scholar
• Walcher D, Marx N. Advanced glycation end products and C peptide-modulators in diabetic vasculopathy and atherogenesis. Semin Immunopathol. 2009;31(1):103–111
   PubMedGoogle Scholar